Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Vaxart, Inc. (VXRT)
USD0.55
+0.00 (+0.00%)
US NASDAQ Healthcare Biotechnology
Address
170 Harbor Way 94080
South San Francisco, CA, US
South San Francisco, CA, US
CEO
Steven Lo
Website
vaxart.com
IPO
1981-12-11
CIK 72444 ISIN US92243A2006
Description
Vaxart, Inc. operates as a biotechnology firm currently in the clinical development phase, concentrating its efforts on identifying and advancing novel oral recombinant protein vaccines. The company leverages its unique proprietary platform for delivering these oral vaccine solutions. Its diverse pipeline showcases several promising candidates: An oral tablet vaccine targeting norovirus, which is presently undergoing Phase Ib clinical assessment for both GI.1 and GII.4 strains. A seasonal influenza vaccine, now in Phase II clinical studies, designed to address H1 influenza infections. A vaccine candidate against respiratory syncytial virus (RSV). A coronavirus vaccine, also advancing through Phase II clinical trials for SARS-CoV-2. Beyond infectious diseases, Vaxart is also engaged in formulating therapeutic vaccines aimed at treating cervical cancer and dysplasia associated with human papillomavirus. The company's main operations are situated in South San Francisco, California.
News Sentiment (7d)
Based on only 1 article — low confidence
Market Cap & Enterprise Value
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD0.55
+0.00 (+0.00%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
396.9K
Beta
1.09
Float Shares
237.71M
Free Float %
98.2%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -7.14% | -13.33% | +3.17% | +16.07% | +80.56% | +85.71% | +60.49% | -38.10% | -90.02% | -96.06% | -99.44% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (3 ratings, all time)
Buy
Price Targets & DCF
Current price
0.55
Low
2.00
+263.6%
Consensus
2.00
+263.6%
Median
2.00
+263.6%
High
2.00
+263.6%
Ratings Trend (MoM)
100% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 3 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Price Target Summary
| Period | # Analysts | Avg Target |
|---|---|---|
| Last Month | — | — |
| Last Quarter | — | — |
| Last Year | — | — |
| All Time | 1 |
2.00
+263.6%
|
Quality scores
Altman Z-Score
0.07
Distress
Piotroski F-Score
5 / 9
Average
MOAT Score
1 / 10
No MOAT
Composite Rating
A
Overall Score
4 / 5
High
DCF Score
1 / 5
Low
ROE Score
5 / 5
High
ROA Score
5 / 5
High
D/E Score
3 / 5
Medium
P/E Score
4 / 5
High
P/Book Score
4 / 5
High
Operational MOAT
✓ MOAT relativo
-
Revenue growth Biotechnology: +1.6%+726.7% ★ Q1'26: +87.9% (vs Q1'25)
-
EPS growth Biotechnology: +29.7%+150.0% ★ Q1'26: +129.2% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%+0.9% Q1'26: -6.4% (vs Q1'25)
-
EBIT margin Biotechnology: +0.0%+8.3% ★ Q1'26: +0.0% (vs Q1'25)
-
ROIC Biotechnology: -16.1%+57.8% ★ Q1'26: +0.0% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%-52.7% ★ Q1'26: +6.3% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×0.32× ★ Q1'26: 0.39× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2002 actual |
Dec 2003 actual |
Dec 2004 actual |
Dec 2005 actual |
Dec 2007 actual |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 2 Rev. Ana. 1 EPS Ana. |
Dec 2028 2 Rev. Ana. 2 EPS Ana. |
Dec 2029 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
195.97M
est: 149.91M (+30.7%)
|
176.57M
est: 98.95M (+78.4%)
|
142.18M
est: 118.25M (+20.2%)
|
108.06M
est: 73.56M (+46.9%)
|
—
est: 83.02M (-100.0%)
|
24.60M
est: 25.98M (-5.3%)
|
9.30M
est: 29.65M (-68.6%)
|
8.90M
est: 8.43M (+5.5%)
|
5.84M
est: 8.43M (-30.8%)
|
4.16M
est: 4.00M (+4.0%)
|
9.86M
est: 6.50M (+51.7%)
|
4.05M
est: 8.05M (-49.7%)
|
892.0K
est: 993.3K (-10.2%)
|
107.0K
est: 792.5K (-86.5%)
|
7.38M
est: 13.93M (-47.0%)
|
28.70M
est: 34.30M (-16.3%)
|
237.26M
est: 21.60M (+998.4%)
|
8.97M
8.97M – 8.97M
-58.5% YoY
|
9.72M
9.72M – 9.72M
+8.4% YoY
|
76.75M
76.75M – 76.75M
+689.7% YoY
|
151.88M
151.88M – 151.88M
+97.9% YoY
|
| EBITDA |
25.86M
est: 37.71M (-31.4%)
|
19.72M
est: 26.39M (-25.3%)
|
-33.87M
est: -18.18M (-86.3%)
|
-107.28M
est: -181.47M (+40.9%)
|
-33.60M
est: -30.08M (-11.7%)
|
-18.10M
est: -25.98M (+30.3%)
|
-25.00M
est: -29.65M (+15.7%)
|
-27.20M
est: -8.43M (-222.5%)
|
-8.74M
est: -8.43M (-3.6%)
|
-12.02M
est: -4.00M (-200.4%)
|
-12.17M
est: -6.50M (-87.2%)
|
-28.26M
est: -21.65M (-30.6%)
|
-66.45M
est: -61.88M (-7.4%)
|
-100.58M
est: -77.29M (-30.1%)
|
-72.13M
est: -10.81M (-567.2%)
|
-54.87M
est: -26.62M (-106.1%)
|
28.21M
est: -16.77M (+268.2%)
|
-6.96M
-6.96M – -6.96M
+58.5% YoY
|
-7.54M
-7.54M – -7.54M
-8.4% YoY
|
-59.57M
-59.57M – -59.57M
-689.7% YoY
|
-117.90M
-117.90M – -117.90M
-97.9% YoY
|
| EBIT |
15.79M
est: 9.71M (+62.7%)
|
5.48M
est: -5.69M (+196.4%)
|
-52.05M
est: -40.83M (-27.5%)
|
-122.64M
est: -218.84M (+44.0%)
|
-35.33M
est: -44.31M (+20.3%)
|
-19.20M
est: -25.98M (+26.1%)
|
-25.10M
est: -29.65M (+15.3%)
|
-27.30M
est: -8.43M (-223.7%)
|
-9.12M
est: -8.43M (-8.1%)
|
-15.22M
est: -4.00M (-280.5%)
|
-15.77M
est: -6.50M (-142.6%)
|
-30.11M
est: -24.26M (-24.1%)
|
-68.88M
est: -69.76M (+1.3%)
|
-106.39M
est: -66.43M (-60.2%)
|
-80.76M
est: -10.91M (-640.1%)
|
-63.72M
est: -26.87M (-137.1%)
|
19.63M
est: -16.92M (+216.0%)
|
-7.02M
-7.02M – -7.02M
+58.5% YoY
|
-7.61M
-7.61M – -7.61M
-8.4% YoY
|
-60.13M
-60.13M – -60.13M
-689.7% YoY
|
-118.99M
-118.99M – -118.99M
-97.9% YoY
|
| Net Income |
2.06M
est: 6.87M (-70.1%)
|
-6.83M
est: -2.49M (-174.4%)
|
-50.39M
est: -58.04M (+13.2%)
|
-128.45M
est: -252.81M (+49.2%)
|
47.07M
est: 72.87M (-35.4%)
|
-19.10M
est: -1.61B (+98.8%)
|
-25.40M
est: -1.15B (+97.8%)
|
-29.40M
est: -4.13B (+99.3%)
|
-12.46M
est: -4.13B (+99.7%)
|
-18.01M
est: -7.93B (+99.8%)
|
-18.65M
est: -321.59M (+94.2%)
|
-32.22M
est: -26.33M (-22.4%)
|
-70.47M
est: -67.35M (-4.6%)
|
-107.76M
est: -83.47M (-29.1%)
|
-82.47M
est: -105.95M (+22.2%)
|
-66.95M
est: -86.78M (+22.9%)
|
16.33M
est: -64.50M (+125.3%)
|
-87.53M
-87.53M – -87.53M
-35.7% YoY
|
-91.42M
-91.42M – -91.42M
-4.4% YoY
|
-83.74M
-93.62M – -73.86M
+8.4% YoY
|
-74.86M
-74.86M – -74.86M
+10.6% YoY
|
| SGA |
38.38M
est: 93.25M (-58.8%)
|
62.25M
est: 6.07B (-99.0%)
|
46.19M
est: 62.40M (-26.0%)
|
37.04M
est: 4.51B (-99.2%)
|
26.09M
est: 25.91M (+0.7%)
|
6.60M
est: 1.59B (-99.6%)
|
5.60M
est: 1.82B (-99.7%)
|
5.70M
est: 517.33M (-98.9%)
|
2.60M
est: 517.33M (-99.5%)
|
6.68M
est: 245.37M (-97.3%)
|
6.19M
est: 398.73M (-98.4%)
|
15.20M
est: 493.82M (-96.9%)
|
21.89M
est: 60.93M (-64.1%)
|
29.39M
est: 48.61M (-39.6%)
|
22.58M
est: 844.13M (-97.3%)
|
20.78M
est: 2.08B (-99.0%)
|
17.61M
est: 1.31B (-98.7%)
|
543.44M
543.44M – 543.44M
-58.5% YoY
|
589.04M
589.04M – 589.04M
+8.4% YoY
|
4.65B
4.65B – 4.65B
+689.7% YoY
|
9.21B
9.21B – 9.21B
+97.9% YoY
|
| EPS |
0.26
est: 0.19 (+38.9%)
|
-0.92
est: -6.03 (+84.7%)
|
-5.68
est: -36.77 (+84.6%)
|
-14.16
est: -99.33 (+85.7%)
|
5.15
est: -45.77 (+111.2%)
|
-0.59
est: -3.30 (+82.0%)
|
-0.72
est: -2.37 (+69.4%)
|
-0.84
est: -8.47 (+90.1%)
|
-0.33
est: -8.47 (+96.1%)
|
-0.29
est: -16.28 (+98.2%)
|
-0.09
est: -0.66 (+87.0%)
|
-0.07
est: -0.28 (+76.0%)
|
-0.14
est: -0.66 (+78.9%)
|
-0.22
est: -0.84 (+73.7%)
|
-0.17
est: -0.46 (+63.0%)
|
-0.14
est: -0.39 (+63.8%)
|
0.07
est: -0.28 (+125.0%)
|
-0.38
-0.38 – -0.38
-35.7% YoY
|
-0.40
-0.40 – -0.40
-4.4% YoY
|
-0.36
-0.41 – -0.32
+8.4% YoY
|
-0.33
-0.33 – -0.33
+10.6% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-07 | A | 4/5 | 1/5 | 5/5 | 5/5 | 3/5 | 4/5 | 4/5 |
| 2026-05-06 | A | 4/5 | 1/5 | 5/5 | 5/5 | 3/5 | 4/5 | 4/5 |
| 2026-05-05 | A | 4/5 | 1/5 | 5/5 | 5/5 | 3/5 | 4/5 | 4/5 |
| 2026-05-04 | A | 4/5 | 1/5 | 5/5 | 5/5 | 3/5 | 4/5 | 4/5 |
| 2026-05-01 | A- | 4/5 | 1/5 | 5/5 | 5/5 | 2/5 | 4/5 | 4/5 |
| 2026-04-30 | A- | 4/5 | 1/5 | 5/5 | 5/5 | 2/5 | 4/5 | 4/5 |
| 2026-04-29 | A- | 4/5 | 1/5 | 5/5 | 5/5 | 2/5 | 4/5 | 4/5 |
| 2026-04-28 | A- | 4/5 | 1/5 | 5/5 | 5/5 | 2/5 | 4/5 | 4/5 |
| 2026-04-27 | A- | 4/5 | 1/5 | 5/5 | 5/5 | 2/5 | 4/5 | 4/5 |
| 2026-04-24 | A- | 4/5 | 1/5 | 5/5 | 5/5 | 2/5 | 4/5 | 4/5 |
| 2026-04-23 | A- | 4/5 | 1/5 | 5/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-22 | A- | 4/5 | 1/5 | 5/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-21 | B+ | 3/5 | 1/5 | 4/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-20 | B+ | 3/5 | 1/5 | 4/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-17 | B+ | 3/5 | 1/5 | 4/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-16 | B+ | 3/5 | 1/5 | 4/5 | 5/5 | 2/5 | 3/5 | 4/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
132.62M
OE per share TTM
0.58
Owner's Yield
77.83%
Maintenance CapEx ratio
191.87%
Maint CapEx / Avg PPE
56.6%
Ownership Overview
Ownership breakdown
At a glance
Institutional holders
2
Total invested
16.2K
Insider transactions (90d)
2
Beneficial owners (>5%)
31
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Peter Kolchinsky | 15.38M | 9.10% | — | 15.38M | — | — | HC, IN | United States of America | 2024-01-19 | ↗ |
| 2 | RA Capital Healthcare Fund, L.P. | 15.38M | 9.10% | — | 15.38M | — | — | PN | United States of America | 2024-01-19 | ↗ |
| 3 | RA Capital Management, L.P. | 15.38M | 9.10% | — | 15.38M | — | — | IA, PN | United States of America | 2024-01-19 | ↗ |
| 4 | Rajeev Shah | 15.38M | 9.10% | — | 15.38M | — | — | HC, IN | United States of America | 2024-01-19 | ↗ |
| 5 | STATE STREET CORPORATION | 11.19M | 8.91% | — | 10.95M | — | 11.19M | HC | BOSTON, MASSACHUSETTS | 2022-02-11 | ↗ |
| 6 | SSGA FUNDS MANAGEMENT, INC. | 8.96M | 7.14% | — | 8.93M | — | 8.96M | IA | BOSTON, MASSACHUSETTS | 2022-02-11 | ↗ |
| 7 | (1) BlackRock, Inc. | 8.45M | 6.70% | 8.34M | — | 8.45M | — | HC | Delaware | 2022-02-07 | ↗ |
| 8 | The Vanguard Group - 23-1945930 | 7.02M | 5.35% | — | — | 6.88M | 144.5K | IA | Pennsylvania | 2023-02-09 | ↗ |
| 9 | Landon T. Clay | 3.41M | 9.70% | — | 3.32M | — | — | IN | United States of America | 2015-02-11 | ↗ |
| 10 | Thomas M. Clay | 3.20M | 8.30% | 3.20M | — | 3.20M | — | IN | United States of America | 2018-02-14 | ↗ |
| 11 | East Hill Management Company, LLC | 2.92M | 7.50% | 2.92M | — | 2.92M | — | OO | United States of America | 2018-02-14 | ↗ |
| 12 | Broadfin Capital, LLC | 2.46M | 7.01% | — | 2.46M | — | 2.46M | IA, OO | Delaware | 2014-08-08 | ↗ |
| 13 | Broadfin Healthcare Master Fund, Ltd. | 2.46M | 7.01% | — | 2.46M | — | 2.46M | CO | Delaware | 2014-08-08 | ↗ |
| 14 | Kevin Kotler | 2.46M | 7.01% | — | 2.46M | — | 2.46M | HC, IN | Delaware | 2014-08-08 | ↗ |
| 15 | Ajay Bhalla | 2.03M | 5.20% | — | 2.03M | — | 2.03M | IN | Delaware | 2016-01-15 | ↗ |
| 16 | John R. Yanuklis | 2.03M | 5.20% | — | 2.03M | — | 2.03M | IN | Delaware | 2016-01-15 | ↗ |
| 17 | Senzar Asset Management, LLC | 2.03M | 5.20% | — | 2.03M | — | 2.03M | IA, OO | Delaware | 2016-01-15 | ↗ |
| 18 | Senzar Healthcare Master Fund, LP | 1.99M | 5.20% | — | 1.99M | — | 1.99M | PN | Delaware | 2016-01-15 | ↗ |
| 19 | Senzar Healthcare Master GP, Ltd. | 1.99M | 5.20% | — | 1.99M | — | 1.99M | CO | Delaware | 2016-01-15 | ↗ |
| 20 | East Hill Hedge Fund, LLC | 1.87M | 5.30% | 1.87M | — | 1.87M | — | OO | Delaware | 2015-02-11 | ↗ |
| 21 | M. Collery | 1.87M | 4.83% | — | 1.87M | — | — | IN | UNITED STATES OF AMERICA | 2018-01-18 | ↗ |
| 22 | A. Hurwitz | 1.83M | 4.74% | — | 1.83M | — | — | IN | UNITED STATES OF AMERICA | 2018-01-18 | ↗ |
| 23 | Fundamental LLC | 1.83M | 4.74% | — | 1.83M | — | — | OO | NEW YORK | 2018-01-18 | ↗ |
| 24 | Fundamental Value Fund, L.P. | 1.83M | 4.74% | — | 1.83M | — | — | PN | DELAWARE | 2018-01-18 | ↗ |
| 25 | H. Koffler | 1.83M | 4.74% | — | 1.83M | — | — | IN | UNITED STATES OF AMERICA | 2018-01-18 | ↗ |
| 26 | T. Bird | 1.83M | 4.74% | — | 1.83M | — | — | IN | UNITED STATES OF AMERICA | 2018-01-18 | ↗ |
| 27 | BML Investment Partners, L.P. | 1.67M | 3.50% | — | 1.67M | — | 1.67M | PN | — | 2020-02-11 | ↗ |
| 28 | HUNTER HALL INVESTMENT MANAGEMENT LTD. | 1.01M | 3.56% | 1.01M | — | 1.01M | — | OO | AUSTRALIA | 2013-12-06 | ↗ |
| 29 | BARCLAYS GLOBAL INVESTORS, NA. | 797.4K | 4.87% | — | 723.3K | — | 723.3K | BK | Cayman Islands | 2019-04-25 | ↗ |
| 30 | Gabelli Funds, LLC | 325.0K | 3.59% | — | 12.83M | — | 13.07M | IA | BOSTON, MASSACHUSETTS | 2022-03-10 | ↗ |
| 31 | Fund Management Profit Sharing Plan | 37.5K | 0.10% | — | 37.5K | — | — | EP | UNITED STATES OF AMERICA | 2018-01-18 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
From
To
13F snapshot — 2026 Q1
Investors holding
2
-3 vs prev Q
New positions
1
Closed positions
4
Increased
1
Reduced
0
Put/Call ratio
0.00
Calls held
—
Puts held
—
Top institutional holders
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | HERITAGE WEALTH ADVISORS | 26.0K +4.0K (+18.2%) | 9.0K +979.0 (+12.2%) | 0.01% +0.002 pp | 0.00% +0.000 pp | USD2.12 -83.5% | 24 qtrs — |
| 2 | LVM CAPITAL MANAGEMENT LTD/MI | 25.0K +— (+0.0%) | 9.0K +— (+0.0%) | 0.01% +0.000 pp | 0.00% +0.000 pp | USD0.70 -50.0% | 11 qtrs — |
| 3 | KINGSWOOD WEALTH ADVISORS, LLC | 10.0K +10.0K (+100.0%) | 3.5K +3.5K (+100.0%) | 0.00% +0.004 pp | 0.00% +0.000 pp | USD0.35 +0.0% | 8 qtrs — |
| 4 | ORG PARTNERS LLC | 2.0K +— (+0.0%) | 692.00 -37.0 (-5.1%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD0.41 -14.6% | 4 qtrs — |
| 5 | ARCHER INVESTMENT CORP | 15.00 +— (+0.0%) | 5.00 +— (+0.0%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD8.80 -96.0% | 23 qtrs — |
| 6 | FARTHER FINANCE ADVISORS, LLC | — -27.0 (-100.0%) | — -10.0 (-100.0%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD— | 2 qtrs SOLD |
| 7 | HBK SORCE ADVISORY LLC | — -75.1K (-100.0%) | — -26.2K (-100.0%) | 0.00% -0.033 pp | 0.00% -0.001 pp | USD— | 11 qtrs SOLD |
| 8 | MARSHALL WACE, LLP | — -2.0M (-100.0%) | — -703.1K (-100.0%) | 0.00% -0.855 pp | 0.00% -0.001 pp | USD— | 3 qtrs SOLD |
| 9 | ROCKEFELLER CAPITAL MANAGEMENT L.P. | — -1.2K (-100.0%) | — -429.0 (-100.0%) | 0.00% -0.001 pp | 0.00% +0.000 pp | USD— | 2 qtrs SOLD |
| 10 | SIMPLEX TRADING, LLC | — -18.6K (-100.0%) | — -6.0K (-100.0%) | 0.00% -0.008 pp | 0.00% +0.000 pp | USD— | 20 qtrs SOLD |
| 11 | UMB BANK, N.A. | — -100.0 (-100.0%) | — -36.0 (-100.0%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD— | 12 qtrs SOLD |
| 12 | WEALTH ENHANCEMENT ADVISORY SERVICES, LLC | — -10.4K (-100.0%) | — -3.7K (-100.0%) | 0.00% -0.005 pp | 0.00% +0.000 pp | USD— | 10 qtrs SOLD |
| 13 | ADVISOR GROUP HOLDINGS, INC. | — -14.2K (-100.0%) | — -5.3K (-100.0%) | 0.00% -0.006 pp | 0.00% +0.000 pp | USD— | 24 qtrs SOLD |
| 14 | XTX TOPCO LTD | — -94.3K (-100.0%) | — -34.4K (-100.0%) | 0.00% -0.041 pp | 0.00% -0.002 pp | USD— | 11 qtrs SOLD |
| 15 | BAADER BANK AKTIENGESELLSCHAFT | — -12.1K (-100.0%) | — -2.7K (-100.0%) | 0.00% -0.005 pp | 0.00% 0.000 pp | USD— | 4 qtrs SOLD |
| 16 | BEACON CAPITAL MANAGEMENT, LLC | — -60.3K (-100.0%) | — -22.0K (-100.0%) | 0.00% -0.026 pp | 0.00% -0.003 pp | USD— | 16 qtrs SOLD |
| 17 | CONCORD WEALTH PARTNERS | — -75.0 (-100.0%) | — -27.0 (-100.0%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD— | 13 qtrs SOLD |
| 18 | CUSTOS FAMILY OFFICE, LLC | — -50.0K (-100.0%) | — -18.2K (-100.0%) | 0.00% -0.022 pp | 0.00% -0.010 pp | USD— | 3 qtrs SOLD |
Ownership breakdown by holder
ETF Ownership
Top ETFs holding this stock
This company is not held by any ETF in our universe.
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
0.00
Bearish
Buys
2
Sells
0
Shares acquired
236.2K
Shares disposed
—
Cash buys
—
Cash sales
—
Net activity
+236,200
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2033-03-17 | Lee Phillip E | Officer | A-Award | A | Stock Option (right to buy) | 410,000 | 0.78 | 319.8K | 410,000 | — | ↗ |
| 2026-04-23 | BREITMEYER JAMES B | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2026-03-28 | Tucker Sean | Officer | F-InKind | D | Common Stock | 3,924 | 0.65 | 2.6K | 882,811 | D | ↗ |
| 2026-03-28 | Cummings James F. | Officer | F-InKind | D | Common Stock | 3,292 | 0.65 | 2.1K | 924,177 | D | ↗ |
| 2026-03-24 | Tucker Sean | Officer | F-InKind | D | Common Stock | 36,418 | 0.69 | 25.3K | 886,735 | D | ↗ |
| 2026-03-24 | Lo Steven | Director / Officer | F-InKind | D | Common Stock | 126,028 | 0.69 | 87.5K | 2,485,606 | D | ↗ |
| 2026-03-24 | Cummings James F. | Officer | F-InKind | D | Common Stock | 30,551 | 0.69 | 21.2K | 927,469 | D | ↗ |
| 2026-03-24 | Berg Edward B | Officer | F-InKind | D | Common Stock | 36,418 | 0.69 | 25.3K | 755,368 | D | ↗ |
| 2026-03-18 | Tucker Sean | Officer | F-InKind | D | Common Stock | 8,072 | 0.63 | 5.1K | 923,153 | D | ↗ |
| 2026-03-18 | Lo Steven | Director / Officer | F-InKind | D | Common Stock | 22,425 | 0.63 | 14.2K | 2,611,634 | D | ↗ |
| 2026-03-18 | Cummings James F. | Officer | F-InKind | D | Common Stock | 6,772 | 0.63 | 4.3K | 958,020 | D | ↗ |
| 2026-03-18 | Berg Edward B | Officer | F-InKind | D | Common Stock | 8,072 | 0.63 | 5.1K | 791,786 | D | ↗ |
| 2026-03-16 | Tucker Sean | Officer | A-Award | A | Common Stock | 200,000 | 0.00 | — | 931,225 | D | ↗ |
| 2026-03-16 | Lo Steven | Director / Officer | A-Award | A | Common Stock | 846,500 | 0.00 | — | 2,634,059 | D | ↗ |
| 2026-03-16 | Grasman Jeroen Nicolaas | Officer | A-Award | A | Stock Option (right to buy) | 455,000 | 0.68 | 309.2K | 455,000 | D | ↗ |
| 2026-03-16 | Cummings James F. | Officer | A-Award | A | Stock Option (right to buy) | 455,000 | 0.68 | 309.2K | 455,000 | D | ↗ |
| 2026-03-16 | Berg Edward B | Officer | A-Award | A | Stock Option (right to buy) | 225,000 | 0.68 | 152.9K | 225,000 | D | ↗ |
| 2026-02-02 | Tucker Sean | Officer | F-InKind | D | Common Stock | 9,265 | 0.61 | 5.6K | 731,225 | D | ↗ |
| 2026-02-02 | Cummings James F. | Officer | F-InKind | D | Common Stock | 7,965 | 0.61 | 4.8K | 737,792 | D | ↗ |
| 2026-02-02 | Berg Edward B | Officer | F-InKind | D | Common Stock | 9,265 | 0.61 | 5.6K | 684,858 | D | ↗ |
| 2025-12-04 | Lo Steven | Director / Officer | A-Award | A | Common Stock | 151,351 | 0.00 | — | 1,841,712 | D | ↗ |
| 2025-11-17 | Watson W. Mark | Director | P-Purchase | A | Common Stock | 5,000 | 0.41 | 2.0K | 124,125 | D | ↗ |
| 2025-11-17 | HERON ELAINE J | Director | P-Purchase | A | Common Stock | 23,217 | 0.39 | 9.1K | 79,783 | D | ↗ |
| 2025-08-15 | Finney Kevin | Director | P-Purchase | A | Common Stock | 50,000 | 0.37 | 18.5K | 204,771 | D | ↗ |
| 2025-07-30 | Finney Kevin | Director | P-Purchase | A | Common Stock | 25,874 | 0.38 | 9.8K | 104,771 | D | ↗ |
| 2025-07-29 | Watson W. Mark | Director | P-Purchase | A | Common Stock | 10,000 | 0.41 | 4.1K | 104,125 | D | ↗ |
| 2025-07-28 | Finney Kevin | Director | P-Purchase | A | Common Stock | 20,000 | 0.40 | 8.0K | 78,897 | D | ↗ |
| 2025-07-25 | Finney Kevin | Director | P-Purchase | A | Common Stock | 20,000 | 0.39 | 7.8K | 58,897 | D | ↗ |
| 2025-07-17 | Finney Kevin | Director | P-Purchase | A | Common Stock | 794 | 0.38 | 301.72 | 38,897 | D | ↗ |
| 2025-06-13 | Wheadon David E. | Director | A-Award | A | Stock Option (right to buy) | 95,400 | 0.70 | 66.8K | 95,400 | D | ↗ |
| 2025-06-13 | Watson W. Mark | Director | A-Award | A | Common Stock | 16,000 | 0.00 | — | 94,125 | D | ↗ |
| 2025-06-13 | HERON ELAINE J | Director | A-Award | A | Common Stock | 16,000 | 0.00 | — | 56,566 | D | ↗ |
| 2025-06-13 | Finney Michael J. | Director | A-Award | A | Stock Option (right to buy) | 95,400 | 0.70 | 66.8K | 95,400 | D | ↗ |
| 2025-06-13 | Finney Kevin | Director | A-Award | A | Stock Option (right to buy) | 36,392 | 0.70 | 25.5K | 36,392 | D | ↗ |
| 2025-05-19 | Lo Steven | Director / Officer | P-Purchase | A | Common Stock | 100,000 | 0.49 | 49.0K | 100,000 | I | ↗ |
| 2025-05-19 | Grasman Jeroen Nicolaas | Officer | A-Award | A | Stock Option (right to buy) | 1,000,000 | 0.50 | 499.8K | 1,000,000 | D | ↗ |
| 2025-03-28 | Tucker Sean | Officer | F-InKind | D | Common Stock | 3,913 | 0.42 | 1.6K | 740,490 | D | ↗ |
| 2025-03-28 | Cummings James F. | Officer | F-InKind | D | Common Stock | 3,292 | 0.42 | 1.4K | 745,757 | D | ↗ |
| 2025-03-24 | Tucker Sean | Officer | A-Award | A | Stock Option (right to buy) | 610,000 | 0.51 | 312.7K | 610,000 | D | ↗ |
| 2025-03-24 | Lo Steven | Director / Officer | A-Award | A | Common Stock | 1,405,000 | 0.00 | — | 1,632,638 | D | ↗ |
| 2025-03-24 | Lee Phillip E | Officer | A-Award | A | Stock Option (right to buy) | 610,000 | 0.51 | 312.7K | 610,000 | D | ↗ |
| 2025-03-24 | Cummings James F. | Officer | A-Award | A | Stock Option (right to buy) | 50,000 | 0.51 | 25.6K | 50,000 | D | ↗ |
| 2025-03-24 | Berg Edward B | Officer | A-Award | A | Common Stock | 406,000 | 0.00 | — | 694,123 | D | ↗ |
| 2025-03-18 | Tucker Sean | Officer | F-InKind | D | Common Stock | 8,050 | 0.57 | 4.6K | 338,403 | D | ↗ |
| 2025-03-18 | Lo Steven | Director / Officer | F-InKind | D | Common Stock | 22,362 | 0.57 | 12.8K | 227,638 | D | ↗ |
| 2025-03-18 | Lee Phillip E | Officer | F-InKind | D | Common Stock | 8,050 | 0.57 | 4.6K | 225,619 | D | ↗ |
| 2025-03-18 | Cummings James F. | Officer | F-InKind | D | Common Stock | 6,772 | 0.57 | 3.9K | 343,049 | D | ↗ |
| 2025-03-18 | Berg Edward B | Officer | F-InKind | D | Common Stock | 8,050 | 0.57 | 4.6K | 288,123 | D | ↗ |
| 2025-02-02 | Tucker Sean | Officer | F-InKind | D | Common Stock | 9,242 | 0.68 | 6.3K | 346,453 | D | ↗ |
| 2025-02-02 | Cummings James F. | Officer | F-InKind | D | Common Stock | 7,964 | 0.68 | 5.4K | 318,837 | D | ↗ |
| 2025-02-02 | Berg Edward B | Officer | F-InKind | D | Common Stock | 9,242 | 0.68 | 6.3K | 261,464 | D | ↗ |
| 2025-01-28 | Finney Kevin | Director | A-Award | A | Stock Option (right to buy) | 190,800 | 0.75 | 143.5K | 190,800 | D | ↗ |
| 2024-12-15 | Lee Phillip E | Officer | F-InKind | D | Common Stock | 6,132 | 0.59 | 3.6K | 233,669 | D | ↗ |
| 2024-06-18 | Watson W. Mark | Director | P-Purchase | A | Common Stock | 20,000 | 0.68 | 13.6K | 78,125 | — | ↗ |
| 2024-06-12 | Lee Phillip E | Officer | F-InKind | D | Common Stock | 2,007 | 0.76 | 1.5K | 239,801 | — | ↗ |
| 2024-06-11 | Yedid Robert A. | Director | A-Award | A | Common Stock | 16,000 | 0.00 | — | 34,490 | — | ↗ |
| 2024-06-11 | Wheadon David E. | Director | A-Award | A | Common Stock | 16,000 | 0.00 | — | 30,750 | — | ↗ |
| 2024-06-11 | Watson W. Mark | Director | A-Award | A | Common Stock | 16,000 | 0.00 | — | 58,125 | — | ↗ |
| 2024-06-11 | HERON ELAINE J | Director | A-Award | A | Stock Option (right to buy) | 95,400 | 0.77 | 73.5K | 95,400 | — | ↗ |
| 2024-06-11 | Finney Michael J. | Director | A-Award | A | Stock Option (right to buy) | 95,400 | 0.77 | 73.5K | 95,400 | — | ↗ |
| 2024-03-28 | Tucker Sean | Officer | F-InKind | D | Common Stock | 3,902 | 1.30 | 5.1K | 355,695 | — | ↗ |
| 2024-03-28 | Cummings James F. | Officer | F-InKind | D | Common Stock | 3,292 | 1.30 | 4.3K | 326,801 | — | ↗ |
| 2024-03-18 | Tucker Sean | Officer | A-Award | A | Stock Option (right to buy) | 410,000 | 1.16 | 475.6K | 410,000 | — | ↗ |
| 2024-03-18 | Lo Steven | Director / Officer | A-Award | A | Stock Option (right to buy) | 1,000,000 | 1.16 | 1.16M | 1,000,000 | — | ↗ |
| 2024-03-18 | Lee Phillip E | Officer | A-Award | A | Common Stock | 90,000 | 0.00 | — | 241,808 | — | ↗ |
| 2024-03-18 | Cummings James F. | Officer | A-Award | A | Common Stock | 90,000 | 0.00 | — | 330,093 | — | ↗ |
| 2024-03-18 | Berg Edward B | Officer | A-Award | A | Common Stock | 90,000 | 0.00 | — | 270,706 | — | ↗ |
| 2024-02-02 | Tucker Sean | Officer | F-InKind | D | Common Stock | 9,220 | 1.20 | 11.1K | 330,122 | — | ↗ |
| 2024-02-02 | Cummings James F. | Officer | F-InKind | D | Common Stock | 7,965 | 1.20 | 9.6K | 240,093 | — | ↗ |
| 2024-02-02 | Berg Edward B | Officer | F-InKind | D | Common Stock | 9,220 | 1.20 | 11.1K | 180,706 | — | ↗ |
| 2023-12-15 | Lee Phillip E | Officer | F-InKind | D | Common Stock | 5,943 | 0.63 | 3.7K | 151,808 | — | ↗ |
| 2023-12-08 | Tucker Sean | Officer | F-InKind | D | Common Stock | 34,288 | 0.71 | 24.3K | 339,342 | — | ↗ |
| 2023-12-08 | Lee Phillip E | Officer | F-InKind | D | Common Stock | 35,151 | 0.71 | 25.0K | 157,751 | — | ↗ |
| 2023-12-08 | Cummings James F. | Officer | F-InKind | D | Common Stock | 31,409 | 0.71 | 22.3K | 248,058 | — | ↗ |
| 2023-12-08 | Berg Edward B | Officer | F-InKind | D | Common Stock | 33,752 | 0.71 | 24.0K | 189,926 | — | ↗ |
| 2023-06-26 | Yedid Robert A. | Director | A-Award | A | Common Stock | 7,375 | 0.00 | — | 18,490 | — | ↗ |
| 2023-06-26 | Wheadon David E. | Director | A-Award | A | Common Stock | 7,375 | 0.00 | — | 14,750 | — | ↗ |
| 2023-06-26 | Watson W. Mark | Director | A-Award | A | Stock Option (right to buy) | 44,224 | 0.74 | 32.7K | 44,224 | — | ↗ |
| 2023-06-26 | HERON ELAINE J | Director | A-Award | A | Common Stock | 6,922 | 0.00 | — | 24,566 | — | ↗ |
| 2023-06-26 | Finney Michael J. | Director | A-Award | A | Common Stock | 7,375 | 0.00 | — | 670,840 | — | ↗ |
| 2023-06-12 | Lee Phillip E | Officer | A-Award | A | Common Stock | 22,500 | 0.00 | — | 192,902 | — | ↗ |
| 2023-03-28 | Tucker Sean | Officer | F-InKind | D | Common Stock | 3,683 | 0.75 | 2.8K | 373,630 | — | ↗ |
| 2023-03-28 | Cummings James F. | Officer | F-InKind | D | Common Stock | 3,267 | 0.75 | 2.5K | 349,821 | D | ↗ |
| 2023-03-17 | Tucker Sean | Officer | A-Award | A | Common Stock | 45,000 | 0.00 | — | 172,631 | — | ↗ |
| 2023-03-17 | Lee Phillip E | Officer | A-Award | A | Common Stock | 56,652 | 0.00 | — | 170,402 | — | ↗ |
| 2023-03-17 | Floroiu Cezar Andrei | Director / Officer | A-Award | A | Common Stock | 100,000 | 0.00 | — | 185,000 | — | ↗ |
| 2023-03-17 | Cummings James F. | Officer | A-Award | A | Stock Option (right to buy) | 205,000 | 0.78 | 159.9K | 205,000 | — | ↗ |
| 2023-03-17 | Berg Edward B | Officer | A-Award | A | Common Stock | 45,000 | 0.00 | — | 45,000 | — | ↗ |
| 2022-12-28 | Watson W. Mark | Director | P-Purchase | A | Common Stock | 20,000 | 0.76 | 15.1K | 20,000 | — | ↗ |
| 2022-12-16 | Lee Phillip E | Officer | A-Award | A | Common Stock | 68,750 | 0.00 | — | 68,750 | — | ↗ |
| 2022-12-15 | Lee Phillip E | — | — | — | — | — | — | — | 0 | — | ↗ |
| 2022-08-25 | HERON ELAINE J | Director | A-Award | A | Stock Option (right to buy) | 88,448 | 3.36 | 297.2K | 88,448 | — | ↗ |
| 2022-08-24 | Yedid Robert A. | Director | G-Gift | D | Common Stock | 4,000 | 0.00 | — | 11,115 | — | ↗ |
| 2022-08-19 | Yedid Robert A. | Director | M-Exempt | D | Stock Option (right to buy) | 8,000 | 0.00 | — | 57,700 | — | ↗ |
| 2022-08-04 | Yedid Robert A. | Director | A-Award | A | Common Stock | 7,375 | 0.00 | — | 11,115 | — | ↗ |
| 2022-08-04 | Wheadon David E. | Director | A-Award | A | Stock Option (right to buy) | 44,224 | 0.00 | — | 44,224 | — | ↗ |
| 2022-08-04 | Watson W. Mark | Director | A-Award | A | Stock Option (right to buy) | 88,448 | 0.00 | — | 88,448 | — | ↗ |
| 2022-08-04 | Finney Michael J. | Director | A-Award | A | Stock Option (right to buy) | 44,224 | 0.00 | — | 44,224 | — | ↗ |
| 2022-08-04 | Davis Todd C | Director | A-Award | A | Stock Option (right to buy) | 44,224 | 0.00 | — | 44,224 | — | ↗ |
| 2022-08-04 | Cherrington Julie M | Director | A-Award | A | Stock Option (right to buy) | 37,280 | 3.91 | 145.8K | 37,280 | — | ↗ |
| 2022-06-22 | Ahmad Fuad | Officer | P-Purchase | A | Common Stock | 5,000 | 3.22 | 16.1K | 5,000 | — | ↗ |
| 2022-05-11 | Ahmad Fuad | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2022-04-22 | Tucker Sean | Officer | M-Exempt | A | Common Stock | 40,000 | 0.77 | 30.8K | 127,631 | — | ↗ |
| 2022-03-28 | Tucker Sean | Officer | A-Award | A | Stock Option (right to buy) | 262,500 | 5.09 | 1.34M | 262,500 | — | ↗ |
| 2022-03-28 | Floroiu Cezar Andrei | Director / Officer | A-Award | A | Common Stock | 85,000 | 0.00 | — | 85,000 | — | ↗ |
| 2022-03-28 | Cummings James F. | Officer | A-Award | A | Common Stock | 43,750 | 0.00 | — | 43,750 | — | ↗ |
| 2022-02-15 | Berg Edward B | Officer | A-Award | A | Stock Option (right to buy) | 285,000 | 5.07 | 1.44M | 285,000 | — | ↗ |
| 2022-02-14 | Berg Edward B | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2022-01-10 | Yedid Robert A. | Director | S-Sale | D | Common Stock | 1,500 | 6.01 | 9.0K | 0 | — | ↗ |
| 2021-12-22 | Davis Todd C | Director | G-Gift | D | Common Stock | 1,470 | 0.00 | — | 118,530 | — | ↗ |
| 2021-11-30 | Echerd Margaret | Officer | M-Exempt | D | Stock Option (right to buy) | 2,936 | 0.77 | 2.3K | 26,416 | — | ↗ |
| 2021-10-12 | Yedid Robert A. | Director | G-Gift | A | Common Stock | 1,500 | 0.00 | — | 1,500 | — | ↗ |
| 2021-09-10 | Echerd Margaret | Officer | M-Exempt | D | Stock Option (Right to Buy) | 1,467 | 0.00 | — | 29,352 | — | ↗ |
| 2021-08-20 | Cherrington Julie M | Director | A-Award | A | Stock Option (right to buy) | 65,700 | 8.34 | 547.9K | 65,700 | — | ↗ |
| 2021-08-10 | Tucker Sean | Officer | S-Sale | D | Common Stock | 5,828 | 10.20 | 59.4K | 51,465 | — | ↗ |
| 2021-08-10 | Echerd Margaret | Officer | M-Exempt | D | Stock Option (right to buy) | 333 | 5.17 | 1.7K | 2,667 | — | ↗ |
| 2021-07-19 | Echerd Margaret | Officer | M-Exempt | D | Stock Option (right to buy) | 1,467 | 0.77 | 1.1K | 32,287 | — | ↗ |
| 2021-06-18 | Finney Michael J. | Director | M-Exempt | D | Stock Option (right to buy) | 12,700 | 0.68 | 8.6K | 0 | — | ↗ |
| 2021-06-16 | Yedid Robert A. | Director | A-Award | A | Stock Option (right to buy) | 15,097 | 7.79 | 117.6K | 15,097 | — | ↗ |
| 2021-06-16 | Wheadon David E. | Director | A-Award | A | Stock Option (right to buy) | 65,700 | 6.54 | 429.7K | 65,700 | — | ↗ |
| 2021-06-16 | WILSON KAREN J | Director | A-Award | A | Stock Option (right to buy) | 15,097 | 7.79 | 117.6K | 15,097 | — | ↗ |
| 2021-06-16 | Tucker Sean | Officer | A-Award | A | Stock Option (right to buy) | 100,000 | 6.27 | 627.0K | 100,000 | — | ↗ |
| 2021-06-16 | Floroiu Cezar Andrei | Director / Officer | A-Award | A | Stock Option (right to buy) | 250,000 | 6.27 | 1.57M | 250,000 | — | ↗ |
| 2021-06-16 | Finney Michael J. | Director | A-Award | A | Stock Option (right to buy) | 15,097 | 7.79 | 117.6K | 15,097 | — | ↗ |
| 2021-06-16 | Echerd Margaret | Officer | A-Award | A | Stock Option (right to buy) | 100,000 | 6.27 | 627.0K | 100,000 | — | ↗ |
| 2021-06-16 | Davis Todd C | Director | A-Award | A | Stock Option (right to buy) | 15,097 | 7.79 | 117.6K | 15,097 | — | ↗ |
| 2021-06-11 | Yedid Robert A. | Director | S-Sale | D | Common Stock | 10,000 | 8.61 | 86.1K | 8,240 | — | ↗ |
| 2021-06-11 | Echerd Margaret | Officer | M-Exempt | D | Stock Option (right to buy) | 334 | 5.17 | 1.7K | 3,333 | — | ↗ |
| 2021-06-09 | Echerd Margaret | Officer | M-Exempt | A | Common Stock | 35,222 | 0.77 | 27.1K | 47,555 | — | ↗ |
| 2021-05-07 | Latour Wouter | Director | M-Exempt | D | Stock Option (right to buy) | 100,000 | 1.70 | 170.0K | 700,000 | — | ↗ |
| 2021-05-06 | Latour Wouter | Director | S-Sale | D | Common Stock | 100,000 | 6.54 | 653.9K | 0 | — | ↗ |
| 2021-04-21 | Wheadon David E. | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2021-03-16 | Tucker Sean | Officer | M-Exempt | A | Common Stock | 1,006 | 6.49 | 6.5K | 48,053 | — | ↗ |
| 2021-03-04 | Latour Wouter | Director | M-Exempt | D | Stock Option (right to buy) | 150,000 | 0.77 | 115.5K | 213,261 | — | ↗ |
| 2020-11-23 | Latour Wouter | Director | S-Sale | D | Common Stock | 333,334 | 6.32 | 2.11M | 0 | — | ↗ |
| 2020-08-25 | WILSON KAREN J | Director | A-Award | A | Stock Option (right to buy) | 65,700 | 6.95 | 456.6K | 65,700 | — | ↗ |
| 2020-08-13 | Tucker Sean | Officer | M-Exempt | A | Common stock | 4,026 | 6.49 | 26.1K | 51,679 | — | ↗ |
| 2020-08-12 | Latour Wouter | Director | X-InTheMoney | A | Common stock | 166,667 | 0.30 | 50.0K | 333,334 | — | ↗ |
| 2020-06-29 | ARMISTICE CAPITAL, LLC | Director | X-InTheMoney | D | Warrants | 0 | 1.10 | — | 0 | — | ↗ |
| 2020-06-26 | ARMISTICE CAPITAL, LLC | Director | S-Sale | D | Common Stock | 18,226,667 | 10.38 | 189.19M | 5,440,000 | — | ↗ |
| 2020-06-15 | Floroiu Cezar Andrei | Director / Officer | A-Award | A | Stock Option (right to buy) | 900,000 | 2.46 | 2.21M | 900,000 | — | ↗ |
| 2020-06-08 | Yedid Robert A. | Director | A-Award | A | Stock Option (right to buy) | 65,700 | 2.39 | 157.0K | 65,700 | — | ↗ |
| 2020-06-08 | Tucker Sean | Officer | A-Award | A | Stock Option (right to buy) | 360,000 | 1.70 | 612.0K | 360,000 | — | ↗ |
| 2020-06-08 | Latour Wouter | Director / Officer | A-Award | A | Stock Option (right to buy) | 900,000 | 1.70 | 1.53M | 900,000 | — | ↗ |
| 2020-06-08 | Floroiu Cezar Andrei | Director | A-Award | A | Stock Option (right to buy) | 54,720 | 1.71 | 93.6K | 54,720 | — | ↗ |
| 2020-06-08 | Finney Michael J. | Director | A-Award | A | Stock Option (right to buy) | 65,700 | 2.39 | 157.0K | 65,700 | — | ↗ |
| 2020-06-08 | Echerd Margaret | Officer | A-Award | A | Stock Option (right to buy) | 315,000 | 1.70 | 535.5K | 315,000 | — | ↗ |
| 2020-06-08 | Davis Todd C | Director | A-Award | A | Stock Option (right to buy) | 65,700 | 2.39 | 157.0K | 65,700 | — | ↗ |
| 2020-06-03 | ARMISTICE CAPITAL, LLC | Director | S-Sale | D | Common Stock | 0 | 0.00 | — | 7,000,000 | — | ↗ |
| 2020-06-02 | ARMISTICE CAPITAL, LLC | Director | S-Sale | D | Common Stock | 0 | 0.00 | — | 7,400,000 | — | ↗ |
| 2020-06-01 | ARMISTICE CAPITAL, LLC | Director | S-Sale | D | Common Stock | 0 | 0.00 | — | 8,200,000 | — | ↗ |
| 2020-05-27 | ARMISTICE CAPITAL, LLC | Director / 10% Owner | S-Sale | D | Common Stock | 0 | 0.00 | — | 8,400,000 | — | ↗ |
| 2020-05-22 | ARMISTICE CAPITAL, LLC | Director / 10% Owner | S-Sale | D | Common Stock | 200,000 | 2.86 | 572.0K | 8,600,000 | — | ↗ |
| 2020-05-21 | ARMISTICE CAPITAL, LLC | Director / 10% Owner | S-Sale | D | Common Stock | 400,000 | 2.97 | 1.19M | 8,800,000 | — | ↗ |
| 2020-05-20 | ARMISTICE CAPITAL, LLC | Director / 10% Owner | S-Sale | D | Common Stock | 0 | 0.00 | — | 9,200,000 | — | ↗ |
| 2020-05-18 | ARMISTICE CAPITAL, LLC | Director / 10% Owner | S-Sale | D | Common Stock | 650,000 | 2.86 | 1.86M | 10,350,000 | — | ↗ |
| 2020-05-15 | ARMISTICE CAPITAL, LLC | Director / 10% Owner | S-Sale | D | Common Stock | 458,639 | 2.82 | 1.29M | 11,000,000 | — | ↗ |
| 2020-05-14 | ARMISTICE CAPITAL, LLC | Director / 10% Owner | S-Sale | D | Common Stock | 834,669 | 3.02 | 2.52M | 11,458,639 | — | ↗ |
| 2020-05-13 | ARMISTICE CAPITAL, LLC | Director / 10% Owner | S-Sale | D | Common Stock | 0 | 0.00 | — | 12,293,308 | — | ↗ |
| 2020-05-12 | ARMISTICE CAPITAL, LLC | Director / 10% Owner | S-Sale | D | Common Stock | 1,581,076 | 3.02 | 4.77M | 12,818,924 | — | ↗ |
| 2020-05-11 | ARMISTICE CAPITAL, LLC | Director / 10% Owner | S-Sale | D | Common Stock | 0 | 0.00 | — | 14,400,000 | — | ↗ |
| 2020-05-08 | ARMISTICE CAPITAL, LLC | Director / 10% Owner | S-Sale | D | Common Stock | 100,000 | 2.52 | 252.0K | 15,700,000 | — | ↗ |
| 2020-05-07 | ARMISTICE CAPITAL, LLC | Director / 10% Owner | S-Sale | D | Common Stock | 0 | 0.00 | — | 15,800,000 | — | ↗ |
| 2020-05-06 | ARMISTICE CAPITAL, LLC | Director / 10% Owner | S-Sale | D | Common Stock | 0 | 0.00 | — | 15,900,000 | — | ↗ |
| 2020-05-05 | ARMISTICE CAPITAL, LLC | Director / 10% Owner | S-Sale | D | Common Stock | 692,531 | 2.66 | 1.84M | 15,950,000 | — | ↗ |
| 2020-05-04 | ARMISTICE CAPITAL, LLC | Director / 10% Owner | S-Sale | D | Common Stock | 0 | 0.00 | — | 16,642,531 | — | ↗ |
| 2020-05-01 | ARMISTICE CAPITAL, LLC | Director / 10% Owner | S-Sale | D | Common Stock | 0 | 0.00 | — | 17,600,000 | — | ↗ |
| 2020-04-30 | ARMISTICE CAPITAL, LLC | Director / 10% Owner | S-Sale | D | Common Stock | 4,434,296 | 2.96 | 13.13M | 18,600,000 | — | ↗ |
| 2020-04-29 | ARMISTICE CAPITAL, LLC | Director / 10% Owner | S-Sale | D | Common Stock | 873,634 | 3.01 | 2.63M | 23,034,296 | — | ↗ |
| 2020-04-28 | Davis Todd C | Director | S-Sale | D | Common stock | 60,000 | 3.28 | 196.5K | 120,000 | — | ↗ |
| 2020-04-28 | ARMISTICE CAPITAL, LLC | Director / 10% Owner | S-Sale | D | Common Stock | 0 | 0.00 | — | 23,907,930 | — | ↗ |
| 2020-04-13 | Floroiu Cezar Andrei | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2019-11-18 | Yedid Robert A. | Director | A-Award | A | Stock Option (right to buy) | 54,720 | 0.31 | 17.0K | 54,720 | — | ↗ |
| 2019-11-18 | Davis Todd C | Director | A-Award | A | Stock Option (right to buy) | 54,720 | 0.31 | 17.0K | 54,720 | — | ↗ |
| 2019-11-05 | ARMISTICE CAPITAL, LLC | Director | P-Purchase | A | Common Stock | 0 | 0.00 | — | 25,200,000 | — | ↗ |
| 2019-10-25 | Yedid Robert A. | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2019-10-25 | Maher Illya Keith | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2019-10-25 | Davis Todd C | Director | — | D | Common stock | 0 | 0.00 | — | 180,000 | — | ↗ |
| 2019-10-11 | Richard John P | Director | P-Purchase | A | Common stock | 20,000 | 0.38 | 7.7K | 20,000 | — | ↗ |
| 2019-10-07 | ARMISTICE CAPITAL, LLC | 10% Owner | P-Purchase | A | Common Stock | 290,000 | 0.37 | 107.3K | 25,000,000 | — | ↗ |
| 2019-10-04 | ARMISTICE CAPITAL, LLC | 10% Owner | P-Purchase | A | Common Stock | 0 | 0.00 | — | 24,710,000 | — | ↗ |
| 2019-10-03 | ARMISTICE CAPITAL, LLC | 10% Owner | P-Purchase | A | Common Stock | 228,720 | 0.34 | 77.8K | 24,436,000 | — | ↗ |
| 2019-10-02 | ARMISTICE CAPITAL, LLC | 10% Owner | P-Purchase | A | Common Stock | 23,913 | 0.36 | 8.6K | 24,207,280 | — | ↗ |
| 2019-10-01 | ARMISTICE CAPITAL, LLC | 10% Owner | P-Purchase | A | Common Stock | 183,367 | 0.35 | 64.2K | 24,183,367 | — | ↗ |
| 2019-09-30 | Latour Wouter | Director / Officer | P-Purchase | A | Common Stock Purchase Warrant | 166,667 | 0.30 | 50.0K | 166,667 | — | ↗ |
| 2019-09-30 | ARMISTICE CAPITAL, LLC | 10% Owner | P-Purchase | A | Common Stock | 1,600,376 | 0.33 | 528.1K | 24,000,000 | — | ↗ |
| 2019-09-27 | ARMISTICE CAPITAL, LLC | 10% Owner | P-Purchase | A | Common Stock | 972,643 | 0.29 | 282.1K | 22,399,624 | — | ↗ |
| 2019-09-26 | ARMISTICE CAPITAL, LLC | 10% Owner | — | I | Common Warrants | 16,666,667 | 0.30 | 5.00M | 0 | — | ↗ |
| 2019-06-12 | VANLENT ANNE | Director | A-Award | A | Stock Option (right to buy) | 9,000 | 0.68 | 6.1K | 9,000 | — | ↗ |
| 2019-06-12 | Richard John P | Director | A-Award | A | Stock Option (right to buy) | 12,700 | 0.68 | 8.6K | 12,700 | — | ↗ |
| 2019-06-12 | Markham Richard J | Director | A-Award | A | Stock Option (right to buy) | 9,000 | 0.68 | 6.1K | 9,000 | — | ↗ |
| 2019-06-12 | Finney Michael J. | Director | A-Award | A | Stock Option (right to buy) | 9,000 | 0.68 | 6.1K | 9,000 | — | ↗ |
| 2019-06-12 | COX GEOFFREY F | Director | A-Award | A | Stock Option (right to buy) | 9,000 | 0.68 | 6.1K | 9,000 | — | ↗ |
| 2019-05-12 | Tucker Sean | Officer | A-Award | A | Stock Option (right to buy) | 124,061 | 0.77 | 95.5K | 124,061 | — | ↗ |
| 2019-05-12 | Latour Wouter | Director / Officer | A-Award | A | Stock Option (right to buy) | 363,261 | 0.77 | 279.7K | 363,261 | — | ↗ |
| 2019-05-12 | Echerd Margaret | Officer | A-Award | A | Stock Option (right to buy) | 70,444 | 0.77 | 54.2K | 70,444 | — | ↗ |
| 2019-04-11 | Tucker Sean | Officer | P-Purchase | A | Common stock | 27,273 | 1.10 | 30.0K | 52,661 | — | ↗ |
| 2019-04-11 | Finney Michael J. | Director | P-Purchase | A | Common Stock | 181,818 | 1.10 | 200.0K | 452,572 | — | ↗ |
| 2019-04-09 | ARMISTICE CAPITAL, LLC | 10% Owner | — | I | Common Warrants | 4,090,909 | 1.10 | 4.50M | 0 | — | ↗ |
| 2019-01-01 | Echerd Margaret | Officer | — | D | Stock Option (right to buy) | 16,000 | 5.17 | 82.7K | 0 | — | ↗ |
Executive team
Top executives
EBIT / Employee
186.9K
Shares Outstanding
241.97M
Executive compensation
Executive compensation (annual)
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2024 | Steven Lo President and Chief Executive Officer | 473.8K | — | 290.0K | 1.04M | 272.0K | 5.6K | 2.09M | 63.97% | ↗ |
| 2 | 2024 | Andrei Floroiu, M.B.A. Former President and Chief Executive Officer | 81.4K | — | 76.7K | 1.03M | — | 745.4K | 1.93M | 57.19% | ↗ |
| 3 | 2024 | James Cummings, M.D. Chief Medical Officer | 488.1K | — | 104.4K | 428.2K | 179.7K | 12.2K | 1.21M | 43.92% | ↗ |
| 4 | 2024 | Sean Tucker, Ph.D. Chief Scientific Officer | 446.3K | — | 104.4K | 428.2K | 164.3K | 11.9K | 1.16M | 46.11% | ↗ |
| 5 | 2024 | Michael J. Finney, Ph.D. Former Interim Chief Executive Officer | 110.5K | — | 12.3K | 66.1K | 46.4K | 70.1K | 305.4K | 25.67% | ↗ |
| 6 | 2023 | Andrei Floroiu, M.B.A. Former President and Chief Executive Officer | 568.3K | — | 286.8K | 801.9K | 198.9K | 10.9K | 1.87M | 58.32% | ↗ |
| 7 | 2023 | Andrei Floroiu Former President and Chief Executive Officer | 568.3K | — | 286.8K | 801.9K | 198.9K | 10.9K | 1.87M | 58.32% | ↗ |
| 8 | 2023 | James Cummings, M.D. Chief Medical Officer | 454.7K | — | 151.6K | 428.8K | 128.1K | 11.7K | 1.17M | 49.40% | ↗ |
| 9 | 2023 | Sean Tucker, Ph.D. Chief Scientific Officer | 428.3K | — | 147.5K | 428.8K | 121.4K | 11.4K | 1.14M | 50.67% | ↗ |
| 10 | 2023 | Sean N. Tucker, Ph.D. Chief Scientific Officer | 428.3K | — | 147.5K | 428.8K | 121.4K | 11.4K | 1.14M | 50.67% | ↗ |
| 11 | 2022 | Andrei Floroiu President and Chief Executive Officer | 532.5K | — | 432.7K | 2.48M | 133.1K | 9.4K | 3.59M | 81.20% | ↗ |
| 12 | 2022 | Andrei Floroiu Former President and Chief Executive Officer | 532.5K | — | 432.7K | 2.48M | 133.1K | 9.4K | 3.59M | 81.20% | ↗ |
| 13 | 2022 | James Cummings, M.D. Chief Medical Officer | 430.0K | — | 222.7K | 1.18M | 86.0K | 11.0K | 1.93M | 72.75% | ↗ |
| 14 | 2022 | Sean N. Tucker, Ph.D. Chief Scientific Officer | 392.4K | — | 222.7K | 1.18M | 78.5K | 10.7K | 1.89M | 74.50% | ↗ |
| 15 | 2021 | Andrei Floroiu President and Chief Executive Officer | 466.7K | — | — | 1.74M | 198.3K | 9.2K | 2.41M | 72.03% | ↗ |
| 16 | 2021 | James Cummings, M.D. Chief Medical Officer | 112.2K | — | — | 2.23M | 36.1K | 3.7K | 2.38M | 93.62% | ↗ |
| 17 | 2021 | Sean N. Tucker, Ph.D. Senior Vice President and Chief Scientific Officer | 362.2K | 123.2K | — | 694.4K | — | 9.4K | 1.19M | 58.39% | ↗ |
| 18 | 2021 | Sean N. Tucker, Ph.D. Chief Scientific Officer | 362.2K | — | — | 694.4K | 123.2K | 9.4K | 1.19M | 58.39% | ↗ |
| 19 | 2021 | Margaret A. Echerd Senior Vice President and | 338.0K | 114.9K | — | 694.4K | — | 11.0K | 1.16M | 59.94% | ↗ |
| 20 | 2020 | Wouter W. Latour, M.D. Former President and Chief Executive Officer | 232.0K | 105.1K | 125.8K | 1.73M | — | 648.8K | 2.84M | 65.35% | ↗ |
| 21 | 2020 | Andrei Floroiu Chief Executive Officer | 227.6K | 126.7K | — | 2.01M | — | — | 2.36M | 85.01% | ↗ |
| 22 | 2020 | Andrei Floroiu President and Chief Executive Officer | 227.6K | 126.7K | — | 2.01M | — | — | 2.36M | 85.01% | ↗ |
| 23 | 2020 | Sean N. Tucker, Ph.D. Chief Scientific Officer | 348.4K | 173.8K | 125.8K | 693.3K | — | 8.6K | 1.35M | 60.68% | ↗ |
| 24 | 2020 | Sean N. Tucker, Ph.D. Senior Vice President and Chief Scientific Officer | 348.4K | 173.8K | 125.8K | 693.3K | — | 8.6K | 1.22M | 66.92% | ↗ |
| 25 | 2020 | Margaret A. Echerd SVP Controller and | 278.3K | 236.3K | 42.5K | 606.6K | — | 8.6K | 1.17M | 55.38% | ↗ |
| 26 | 2020 | Margaret A. Echerd Senior Vice President and | 278.3K | 236.3K | 42.5K | 606.6K | — | 8.6K | 1.13M | 57.46% | ↗ |
| 27 | 2019 | Wouter W. Latour, M.D. President and Chief Executive Officer | 485.0K | 52.5K | — | 201.8K | — | 8.4K | 747.7K | 26.98% | ↗ |
| 28 | 2019 | Wouter W. Latour, M.D. Former President and Chief Executive Officer | 485.0K | 52.5K | — | 201.8K | — | 8.4K | 747.7K | 26.98% | ↗ |
| 29 | 2019 | Sean N. Tucker, Ph.D. Senior Vice President and Chief Scientific Officer | 331.8K | 21.6K | — | 82.5K | — | 8.8K | 444.7K | 18.56% | ↗ |
| 30 | 2019 | Sean N. Tucker, Ph.D. Chief Scientific Officer | 331.8K | 21.6K | — | 68.3K | — | 8.8K | 430.4K | 15.87% | ↗ |
| 31 | 2019 | Margaret A. Echerd SVP Controller and | 265.0K | 17.2K | — | 38.8K | — | 8.0K | 329.0K | 11.79% | ↗ |
| 32 | 2019 | Margaret A. Echerd Senior Vice President and | 265.0K | 17.2K | — | 38.8K | — | 8.0K | 329.0K | 11.79% | ↗ |
| 33 | 2019 | Margaret A. Echerd VP Controller and Principal Accounting Officer | 265.0K | 17.2K | — | 38.8K | — | 8.0K | 329.0K | 11.79% | ↗ |
| 34 | 2018 | Joseph M. Patti, M.S.P.H, Ph.D. Former President and Chief Executive Officer | 64.4K | — | — | — | — | 1.09M | 1.16M | 0.00% | ↗ |
| 35 | 2018 | Wouter W. Latour, M.D. Former President and Chief Executive Officer | 450.0K | — | — | 392.2K | — | 8.3K | 850.4K | 46.11% | ↗ |
| 36 | 2018 | Wouter W. Latour, M.D. President and Chief Executive Officer | 450.0K | — | — | 392.2K | — | 8.3K | 850.4K | 46.11% | ↗ |
| 37 | 2018 | Mark P. Colonnese Former Executive Vice President and Chief Financial Officer | 43.7K | — | — | — | — | 595.7K | 639.4K | 0.00% | ↗ |
| 38 | 2018 | John M. Harland Former Chief Financial Officer | 310.0K | 35.0K | — | 64.8K | — | 8.3K | 418.0K | 15.50% | ↗ |
| 39 | 2018 | Sean N. Tucker, Ph.D. Chief Scientific Officer | 319.0K | — | — | 50.4K | — | 8.6K | 378.0K | 13.33% | ↗ |
| 40 | 2017 | Joseph M. Patti, M.S.P.H, Ph.D. Former President and Chief Executive Officer | 515.0K | — | — | 426.6K | — | 14.0K | 955.6K | 44.65% | ↗ |
| 41 | 2017 | Mark P. Colonnese Former Executive Vice President and Chief Financial Officer | 349.8K | — | — | 262.5K | — | 13.7K | 626.0K | 41.94% | ↗ |
| 42 | 2016 | Joseph M. Patti, Ph.D. Presid e nt, Ch i ef Executive Officer and D i rector | 500.0K | — | — | 340.4K | 137.5K | 32.5K | 1.01M | 33.69% | ↗ |
| 43 | 2016 | Joseph M. Patti, M.S.P.H, Ph.D. Former President and Chief Executive Officer | 500.0K | — | — | 340.4K | 137.5K | 32.5K | 1.01M | 33.69% | ↗ |
| 44 | 2016 | Mark P. Colonnese Executive Vice President a nd Chief Financial Officer | 233.8K | — | — | 291.7K | 48.4K | 176.1K | 749.9K | 38.90% | ↗ |
| 45 | 2016 | Mark P. Colonnese Former Executive Vice President and Chief Financial Officer | 233.8K | — | — | 291.7K | 48.4K | 176.1K | 749.9K | 38.90% | ↗ |
| 46 | 2016 | Russell H. Plumb Former Executive Cha i rman and | 60.9K | — | — | — | — | — | 60.9K | 0.00% | ↗ |
| 47 | 2015 | Joseph M. Patti, Ph.D. Presid e nt, Ch i ef Executive Officer and D i rector | 477.0K | — | — | 797.1K | 431.3K | 32.8K | 1.74M | 45.86% | ↗ |
| 48 | 2015 | Joseph M. Patti President, Chief Executive Officer and Director | 477.0K | 431.3K | — | 797.1K | — | 32.8K | 1.48M | 53.88% | ↗ |
| 49 | 2015 | Russell H. Plumb Executive Chairman and Director | 318.8K | 172.5K | 98.0K | — | — | 30.1K | 878.1K | 11.16% | ↗ |
| 50 | 2015 | Russell H. Plumb Former Executive Cha i rman and | 318.8K | — | 98.0K | — | 172.5K | 30.1K | 619.3K | 15.82% | ↗ |
| 51 | 2014 | Russell H. Plumb Former Executive Cha i rman and | 525.0K | — | 192.3K | 239.0K | — | 28.3K | 984.5K | 43.80% | ↗ |
| 52 | 2014 | Russell H. Plumb President, Chief Executive Officer and Director | 525.0K | — | 192.3K | 239.0K | — | 28.3K | 984.5K | 43.80% | ↗ |
| 53 | 2014 | Russell H. Plumb Executive Chairman and Director | 525.0K | — | 192.3K | 239.0K | — | 28.3K | 984.5K | 43.80% | ↗ |
| 54 | 2014 | Joseph M. Patti, Ph.D. Presid e nt, Ch i ef Executive Officer and D i rector | 408.0K | — | 120.2K | 149.4K | — | 26.0K | 703.5K | 38.31% | ↗ |
| 55 | 2014 | Joseph M. Patti President, Chief Executive Officer and Director | 408.0K | — | 120.2K | 149.4K | — | 26.0K | 703.5K | 38.31% | ↗ |
| 56 | 2014 | Joseph M. Patti Executive Vice President, Corporate Development and Strategy | 408.0K | — | 120.2K | 149.4K | — | 26.0K | 703.5K | 38.31% | ↗ |
| 57 | 2013 | Russell H. Plumb President, Chief Executive Officer and Director | 335.2K | 60.0K | 583.3K | 1.37M | — | 19.4K | 2.36M | 82.46% | ↗ |
| 58 | 2013 | Russell H. Plumb President, Chief Executive Officer and Director | 335.2K | 60.0K | 583.3K | 1.37M | — | 19.4K | 2.36M | 82.46% | ↗ |
| 59 | 2013 | Joseph M. Patti Executive Vice President, Corporate Development and Strategy | 255.4K | 37.5K | 291.7K | 853.6K | — | 17.2K | 1.46M | 78.69% | ↗ |
| 60 | 2013 | Joseph M. Patti Executive Vice President, Corporate Development and Strategy | 255.4K | 37.5K | 291.7K | 853.6K | — | 17.2K | 1.46M | 78.69% | ↗ |
| 61 | 2013 | Paul Kessler, M.D. Former Sr. Vice President, Clinical, Medical and Regulatory Affairs and Chief Medical Officer | — | — | — | — | — | — | — | — | ↗ |
| 62 | 2013 | Raafat E.F. Fahim, Ph.D. Former President and Chief Executive Officer | — | — | — | — | — | — | — | — | ↗ |
| 63 | 2013 | Matthew Kalnik, Ph.D. Former Sr. Vice President, Strategic Planning Business Operations | — | — | — | — | — | — | — | — | ↗ |
| 64 | 2012 | Raafat E.F. Fahim, Ph.D. Former President and Chief Executive Officer | 422.9K | — | — | — | — | 2.60M | 3.03M | 0.00% | ↗ |
| 65 | 2012 | Paul Kessler, M.D. Former Sr. Vice President, Clinical, Medical and Regulatory Affairs and Chief Medical Officer | 208.1K | — | — | — | — | 1.16M | 1.36M | 0.00% | ↗ |
| 66 | 2012 | Matthew Kalnik, Ph.D. Former Sr. Vice President, Strategic Planning Business Operations | 189.2K | — | — | — | — | 1.07M | 1.26M | 0.00% | ↗ |
| 67 | 2011 | Paul Kessler, M.D. Former Sr. Vice President, Clinical, Medical and Regulatory Affairs and Chief Medical Officer | 347.7K | 20.2K | 209.2K | 243.0K | — | 22.0K | 842.1K | 53.69% | ↗ |
| 68 | 2011 | Matthew Kalnik, Ph.D. Former Sr. Vice President, Strategic Planning Business Operations | 316.1K | 18.4K | 174.3K | 162.0K | — | 22.0K | 692.8K | 48.54% | ↗ |
| 69 | 2010 | Raafat Fahim, Ph.D. President Chief Executive Officer and Acting Chief Financial Officer | 490.1K | — | 133.3K | 300.5K | 370.8K | 319.5K | 1.61M | 26.87% | ↗ |
| 70 | 2010 | Paul Kessler, M.D. Senior Vice President Clinical, Medical and Regulatory Affairs | 340.8K | — | 119.2K | 256.4K | 177.7K | 30.6K | 924.7K | 40.62% | ↗ |
| 71 | 2010 | Matthew Kalnik, Ph.D. Senior Vice President Strategic Planning and Business Operations | 306.9K | — | 51.2K | 97.2K | 162.8K | 30.9K | 649.0K | 22.86% | ↗ |
| 72 | 2009 | Raafat Fahim, Ph.D. President Chief Executive Officer and Acting Chief Financial Officer | 476.3K | — | 157.1K | 207.8K | 623.1K | 243.9K | 1.71M | 21.36% | ↗ |
| 73 | 2009 | Raafat Fahim, Ph.D. President, Chief Executive Officer and Acting Chief Financial Officer | 476.3K | — | 157.1K | 207.8K | 623.1K | 243.9K | 1.71M | 21.36% | ↗ |
| 74 | 2009 | Paul Kessler, M.D. Senior Vice President Clinical, Medical and Regulatory Affairs | 320.8K | — | 92.9K | 190.5K | 181.5K | 46.3K | 832.0K | 34.06% | ↗ |
| 75 | 2009 | Matthew Kalnik, Ph.D. Senior Vice President Strategic Planning and Business Operations | 291.4K | — | 34.6K | 50.7K | 215.0K | 46.8K | 638.4K | 13.36% | ↗ |
| 76 | 2008 | Raafat Fahim, Ph.D. President, Chief Executive Officer and Acting Chief Financial Officer | 458.3K | — | 402.6K | 139.0K | 364.0K | 183.3K | 1.81M | 29.87% | ↗ |
| 77 | 2008 | Raafat Fahim, Ph.D. President Chief Executive Officer and Acting Chief Financial Officer | 458.3K | — | 402.6K | 139.0K | 364.0K | 183.3K | 1.81M | 29.87% | ↗ |
| 78 | 2008 | Paul Kessler, M.D. Senior Vice President Clinical, Medical and Regulatory Affairs | 297.8K | — | 70.4K | 118.6K | 158.1K | 15.4K | 795.2K | 23.77% | ↗ |
| 79 | 2008 | Paul Kessler, Ph.D. | 297.8K | — | 70.4K | 118.6K | 158.1K | 15.4K | 660.3K | 28.63% | ↗ |
| 80 | 2008 | Leslie Hudson, Ph.D. Former Interim President and Chief Executive Officer | 64.6K | 50.0K | 59.1K | — | 190.0K | 45.0K | 408.8K | 14.46% | ↗ |
| 81 | 2008 | Jordan Siegel Former Senior Vice President of Finance and Administration, Chief Financial Officer and Chief Accounting Officer | 78.0K | 42.9K | 213.0K | — | — | 32.0K | 365.8K | 58.21% | ↗ |
| 82 | 2008 | Matthew Kalnik, Ph.D. Senior Vice President Strategic Planning and Business Operations | — | — | — | — | — | — | — | — | ↗ |
| 83 | 2007 | Thomas H. McLain Former Chairman, | 150.9K | — | 199.2K | 36.3K | 106.9K | 1.21M | 1.71M | 13.80% | ↗ |
| 84 | 2007 | Leslie Hudson, Ph.D. Former Interim President and Chief Executive Officer | 419.1K | 164.8K | 238.3K | — | 25.2K | 127.7K | 975.1K | 24.44% | ↗ |
| 85 | 2007 | Leslie Hudson, Ph.D. Former Interim President and Chief Executive Officer | 419.1K | 164.8K | 238.3K | — | 25.2K | 127.7K | 975.1K | 24.44% | ↗ |
| 86 | 2007 | Raafat E.F. Fahim, Ph.D. Chief Executive Officer and President | 344.5K | — | 150.3K | 131.6K | 266.2K | 52.1K | 944.8K | 29.84% | ↗ |
| 87 | 2007 | Raafat Fahim, Ph.D. President, Chief Executive Officer and Acting Chief Financial Officer | 344.5K | — | 150.3K | 131.6K | 266.2K | 52.1K | 944.8K | 29.84% | ↗ |
| 88 | 2007 | Jordan Siegel Former Senior Vice President of Finance and Administration, Chief Financial Officer and Chief Accounting Officer | 317.6K | — | 187.3K | 191.1K | 154.4K | 56.7K | 907.1K | 41.71% | ↗ |
| 89 | 2007 | Jordan I. Siegel Former Senior Vice President of | 317.6K | — | 187.3K | 191.1K | 154.4K | 56.7K | 907.1K | 41.71% | ↗ |
| 90 | 2007 | Henrik S. Rasmussen, M.D., Ph.D. Former Senior Vice President, | 78.2K | — | — | — | — | 11.4K | 89.6K | 0.00% | ↗ |
| 91 | 2007 | Paul Kessler, M.D. Senior Vice President Clinical, Medical and Regulatory Affairs | — | — | — | — | — | — | — | — | ↗ |
| 92 | 2007 | Matthew Kalnik, Ph.D. Senior Vice President Strategic Planning and Business Operations | — | — | — | — | — | — | — | — | ↗ |
| 93 | 2006 | Thomas H. McLain Former Chairman, | 487.5K | 225.0K | 174.2K | 89.7K | 230.9K | 109.3K | 1.32M | 20.05% | ↗ |
| 94 | 2006 | Thomas H. McLain Former Chairman, Chief Executive Officer and President | 487.5K | 225.0K | 89.7K | 115.8K | 230.9K | 109.3K | 1.26M | 16.34% | ↗ |
| 95 | 2006 | Raafat E.F. Fahim, Ph.D. Chief Executive Officer and President | 310.5K | 145.0K | 100.3K | 79.8K | 115.8K | 75.4K | 826.8K | 21.78% | ↗ |
| 96 | 2006 | Raafat Fahim, Ph.D. President, Chief Executive Officer and Acting Chief Financial Officer | 310.5K | 145.0K | 100.3K | 79.8K | 115.8K | 75.4K | 826.8K | 21.78% | ↗ |
| 97 | 2006 | Henrik S. Rasmussen, M.D., Ph.D. Former Senior Vice President, | 310.2K | 145.0K | 100.3K | 77.5K | 107.8K | 67.8K | 808.6K | 21.99% | ↗ |
| 98 | 2006 | Raafat E.F. Fahim, Ph.D. Senior Vice President, Technical and Production Operations | 310.5K | 145.0K | 100.3K | 41.3K | 115.8K | 75.4K | 788.4K | 17.97% | ↗ |
| 99 | 2006 | Henrik S. Rasmussen, M.D., Ph.D. Former Senior Vice President, Clinical, Medical, and Regulatory Affairs | 310.2K | 145.0K | 100.3K | 41.3K | 107.8K | 67.8K | 772.5K | 18.34% | ↗ |
| 100 | 2006 | Jordan I. Siegel Senior Vice President, Finance, Chief Financial Officer and Treasurer | 167.3K | 50.0K | 59.5K | 19.5K | 91.1K | 42.2K | 429.7K | 18.39% | ↗ |
| 101 | 2006 | Jordan Siegel Former Senior Vice President of Finance and Administration, Chief Financial Officer and Chief Accounting Officer | 167.3K | 50.0K | 59.5K | 19.5K | 91.1K | 42.2K | 429.7K | 18.39% | ↗ |
| 102 | 2006 | Jordan I. Siegel Former Senior Vice President of | 167.3K | 50.0K | 59.5K | 19.5K | 91.1K | 42.2K | 429.6K | 18.39% | ↗ |
| 103 | 2006 | Adam E. Logal Former Interim Chief Financial Officer | 153.2K | 90.0K | 10.9K | 24.0K | 44.8K | 12.8K | 335.7K | 10.40% | ↗ |
| 104 | 2006 | Joseph Johnson Former Senior Vice President, People, Process and Technology | 129.3K | — | — | — | — | 180.7K | 309.9K | 0.00% | ↗ |
| 105 | 2006 | Mark L. Smith Former Senior Vice President, Finance, Chief Financial Officer, Chief Accounting Officer, and Treasurer | 60.0K | — | — | — | 13.4K | 6.7K | 80.1K | 0.00% | ↗ |
| 106 | 2005 | Thomas H. McLain Chairman, Chief Executive Officer and President | 459.9K | — | — | 150.0K | — | 43.6K | 503.5K | 29.79% | ↗ |
| 107 | 2005 | Henrik S. Rasmussen, M.D., Ph.D. Senior Vice President, Clinical, Medical, and Regulatory Affairs | 292.8K | — | — | — | — | 31.9K | 324.7K | 0.00% | ↗ |
| 108 | 2005 | Raafat E.F. Fahim, Ph.D. Senior Vice President, Technical and Production Operations | 288.7K | — | — | — | — | 34.5K | 323.2K | 0.00% | ↗ |
| 109 | 2005 | H. LeRoux Jooste Senior Vice President, Global Sales and Marketing | 295.6K | — | — | — | — | 18.7K | 314.2K | 0.00% | ↗ |
| 110 | 2005 | Mark L. Smith Senior Vice President, Finance, Chief Financial Officer, Chief Accounting Officer, and Treasurer | 280.8K | — | — | 75.0K | — | 31.2K | 312.0K | 24.04% | ↗ |
| 111 | 2004 | Thomas H. McLain Chairman, Chief Executive Officer and President | 435.1K | 312.2K | — | 118.2K | — | 38.9K | 786.3K | 15.04% | ↗ |
| 112 | 2004 | Henrik S. Rasmussen, M.D., Ph.D. Senior Vice President, Clinical, Medical, and Regulatory Affairs | 283.6K | 136.6K | — | 214.3K | — | 31.7K | 451.9K | 47.41% | ↗ |
| 113 | 2004 | Mark L. Smith Senior Vice President, Finance, Chief Financial Officer, Chief Accounting Officer, and Treasurer | 273.0K | 128.4K | — | 54.5K | — | 27.6K | 429.0K | 12.70% | ↗ |
| 114 | 2004 | Raafat E.F. Fahim, Ph.D. Senior Vice President, Technical and Production Operations | 271.6K | 131.6K | — | 211.3K | — | 22.1K | 425.2K | 49.68% | ↗ |
| 115 | 2004 | Gary A. Siskowski Former Senior Vice President, Sales and Marketing | 215.4K | 104.2K | — | 40.7K | — | 29.6K | 349.2K | 11.65% | ↗ |
| 116 | 2004 | Richard G. Clark Senior Vice President, Administration and Chief Administration Officer | 158.2K | 127.1K | — | 125.0K | — | 15.6K | 300.8K | 41.55% | ↗ |
| 117 | 2004 | H. LeRoux Jooste Senior Vice President, Global Sales and Marketing | 11.2K | 30.0K | — | 200.0K | — | — | 41.2K | 485.98% | ↗ |
| 118 | 2003 | David J. Gury Former Chief Executive Officer | 359.4K | — | — | 119.4K | — | 3.59M | 3.95M | 3.02% | ↗ |
| 119 | 2003 | Thomas H. McLain President and Chief Executive Officer | 342.0K | 232.1K | — | 60.9K | — | 36.8K | 610.9K | 9.97% | ↗ |
| 120 | 2003 | Thomas H. McLain Chairman, Chief Executive Officer and President | 342.0K | 232.1K | — | 60.9K | — | 36.8K | 610.9K | 9.97% | ↗ |
| 121 | 2003 | Mark L. Smith Senior Vice President, Finance, Chief Financial Officer, Chief Accounting Officer, and Treasurer | 248.9K | 132.2K | — | 41.2K | — | 26.6K | 407.7K | 10.11% | ↗ |
| 122 | 2003 | Henrik S. Rasmussen, M.D., Ph.D. Senior Vice President, Clinical, Medical, and Regulatory Affairs | 221.7K | 143.7K | — | 40.0K | — | 8.2K | 373.6K | 10.71% | ↗ |
| 123 | 2003 | Raafat E.F. Fahim, Ph.D. Senior Vice President, Technical and Production Operations | 189.2K | 125.3K | — | 40.0K | — | 8.3K | 322.8K | 12.39% | ↗ |
| 124 | 2003 | Gary A. Siskowski Former Senior Vice President, Sales and Marketing | 198.3K | 79.6K | — | 32.3K | — | 20.7K | 298.6K | 10.82% | ↗ |
| 125 | 2003 | Gary A. Siskowski Senior Vice President, Sales and Marketing | 198.3K | 79.6K | — | 32.3K | — | 20.7K | 298.6K | 10.82% | ↗ |
| 126 | 2003 | H. LeRoux Jooste Senior Vice President, Global Sales and Marketing | — | — | — | — | — | — | — | — | ↗ |
| 127 | 2003 | Richard G. Clark Senior Vice President, Administration and Chief Administration Officer | — | — | — | — | — | — | — | — | ↗ |
| 128 | 2002 | David J. Gury Former Chief Executive Officer | 483.0K | 384.9K | — | 130.9K | — | 35.5K | 903.3K | 14.50% | ↗ |
| 129 | 2002 | Thomas H. McLain Chairman, Chief Executive Officer and President | 274.6K | 225.5K | — | 62.3K | — | 30.2K | 530.3K | 11.76% | ↗ |
| 130 | 2002 | Thomas H. McLain President and Chief Executive Officer | 274.6K | 225.5K | — | 62.3K | — | 30.2K | 530.3K | 11.76% | ↗ |
| 131 | 2002 | Mark L. Smith Senior Vice President, Finance, Chief Financial Officer, Chief Accounting Officer, and Treasurer | 208.7K | 118.9K | — | 35.3K | — | 8.2K | 335.8K | 10.52% | ↗ |
| 132 | 2002 | Gary A. Siskowski Former Senior Vice President, Sales and Marketing | 190.2K | 85.2K | — | 33.8K | — | 20.8K | 296.2K | 11.42% | ↗ |
| 133 | 2002 | Gary A. Siskowski Senior Vice President, Sales and Marketing | 190.2K | 85.2K | — | 33.8K | — | 20.8K | 296.2K | 11.42% | ↗ |
| 134 | 2002 | Raafat E.F. Fahim, Ph.D. Senior Vice President, Technical and Production Operations | — | — | — | — | — | — | — | — | ↗ |
| 135 | 2002 | Henrik S. Rasmussen, M.D., Ph.D. Senior Vice President, Clinical, Medical, and Regulatory Affairs | — | — | — | — | — | — | — | — | ↗ |
| 136 | 2002 | Richard G. Clark Senior Vice President, Administration and Chief Administration Officer | — | — | — | — | — | — | — | — | ↗ |
| 137 | 2001 | David J. Gury Former Chief Executive Officer | 476.8K | 900.3K | — | 185.3K | — | 52.9K | 1.43M | 12.96% | ↗ |
| 138 | 2001 | Thomas H. McLain President and Chief Executive Officer | 252.2K | 420.0K | — | 191.1K | — | 20.6K | 692.7K | 27.59% | ↗ |
| 139 | 2001 | Thomas H. McLain President and Chief Operating Officer | 252.2K | 420.0K | — | 191.1K | — | 20.6K | 692.7K | 27.59% | ↗ |
| 140 | 2001 | Mark L. Smith Senior Vice President, Finance, Chief Financial Officer, Chief Accounting Officer, and Treasurer | 191.7K | 155.9K | — | 90.2K | — | 9.6K | 357.2K | 25.26% | ↗ |
| 141 | 2001 | Gary A. Siskowski Senior Vice President, Sales and Marketing | 156.7K | 93.7K | — | 17.5K | — | 9.9K | 260.3K | 6.72% | ↗ |
| 142 | 2001 | Raafat E.F. Fahim, Ph.D. Senior Vice President, Technical and Production Operations | — | — | — | — | — | — | — | — | ↗ |
| 143 | 2001 | Henrik S. Rasmussen, M.D., Ph.D. Senior Vice President, Clinical, Medical, and Regulatory Affairs | — | — | — | — | — | — | — | — | ↗ |
| 144 | 2000 | Thomas H. McLain President and Chief Operating Officer | 205.1K | 36.9K | — | 78.4K | — | 15.6K | 257.6K | 30.42% | ↗ |
| 145 | 2000 | Mark L. Smith Senior Vice President, Finance, Chief Financial Officer, Chief Accounting Officer, and Treasurer | — | — | — | — | — | — | — | — | ↗ |
CEO compensation breakdown
Proxy statements
Proxy statements (DEF 14A)
| Filing date | Form type | Filing |
|---|---|---|
| 2025-09-08 | DEFA14A | ↗ |
| 2025-08-21 | DEFA14A | ↗ |
| 2025-08-15 | DEFA14A | ↗ |
| 2025-08-08 | DEFA14A | ↗ |
| 2025-08-06 | DEF 14A | ↗ |
| 2025-07-24 | PRE 14A | ↗ |
| 2025-05-29 | PRE 14A | ↗ |
| 2025-05-29 | DEFA14A | ↗ |
| 2025-05-28 | DEFA14A | ↗ |
| 2025-05-16 | DEFA14A | ↗ |
| 2025-05-16 | DEFA14A | ↗ |
| 2025-05-12 | DEFA14A | ↗ |
| 2025-05-05 | DEFA14A | ↗ |
| 2025-04-28 | DEFA14A | ↗ |
| 2025-04-10 | DEFA14A | ↗ |
| 2025-04-10 | DEF 14A | ↗ |
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Steven Lo | President, Chief Executive Officer & Director | 879.3K | male |
| James F. Cummings | Chief Medical Officer | 679.9K | — |
| Sean N. Tucker | Senior Vice President & Chief Scientific Officer | 622.4K | — |
| Edward Berg | Senior Vice President & General Counsel | — | male |
| Shaily Jaini Garg | Senior Vice President of Clinical Development & Project Management | — | female |
| Rajesh Kapoor | Senior Vice President of Quality | — | — |
| Jeroen Grasman | Chief Financial Officer, Principal Accounting Officer & Principal Financial Officer | — | male |
| Laurie Hastings | Senior Vice President of Human Resources | — | female |
ESG Rating
ESG Score History BIOTECHNOLOGY
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for VXRT
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
